Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis announces positive Rasilez trial results

Novartis announces positive Rasilez trial results

2nd April 2008

Novartis has announced positive clinical trial results for Rasilez (aliskiren) at the meeting of the American College of Cardiology in Chicago.

Data from the Allay study shows that the compound reduces left ventricular hypertrophy as effectively as the current standard treatment, the latest results to show the potential of the compound in the prevention of kidney and heart disease.

In total, 460 overweight patients with high blood pressure and left ventricular hypertrophy from eight countries were involved in the trial that compared Rasilez to angiotensin receptor blocker losartan.

Rasilez is a first-in-class direct renin inhibitor that is currently approved in over 40 countries and provides a robust reduction in blood pressure that lasts for over 24 hours.

Dr Scott Solomon, director of non-invasive cardiology at Brigham and Women’s Hospital, said: “Allay is our first proof that direct renin inhibition, and aliskiren in particular, reduces thickening of heart muscle which is a key risk factor for heart disease.”

He added that this characteristic is vital as it provides patients and doctors with an alternative treatment for left ventricular hypertrophy while also providing an effective means of lowering blood pressure.

In September 2007, Novartis announced the results of the Aloft study showing that Rasilez can potentially reduce the severity of heart failure, with patients in the trial exhibiting reductions in the secretions of brain natriuertic peptide.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.